Richard Haynes joins Protas as Chief Scientist 

Protas is delighted to announce the appointment of Professor Richard Haynes MBE DM FRCP to its Executive Team as its inaugural Chief Scientist.

Richard joins Protas this month to head up the Science Team. As well as providing strategic leadership to the team, he will work with Protas’ partners and collaborators to advise on the design and delivery of large, late-stage, randomised clinical trials, in a way that reduces cost and complexity and increases value. 

As Professor of Renal Medicine and Clinical Trials at Oxford University’s research department, Oxford Population Health, and a consultant kidney doctor in the NHS, Richard brings a wealth of knowledge and expertise to Protas.  

He has led large, randomised trials for over 15 years in cardiovascular, kidney and infectious diseases, and has a keen interest in ensuring that all areas of health benefit from streamlined trials. 

Professor Richard Haynes said: “The NHS and healthcare systems worldwide need better evidence on which to base the important clinical decisions their staff have to make every day. 

“Clinical trials are rapidly becoming too expensive and complex to run, which means fewer trials get done. I look forward to helping Protas deliver streamlined trials which can drive up quality while reducing costs by bringing my experience in running such trials.” 

Richard will work closely with Protas Chief Executive Prof Sir Martin Landray and the wider Executive Team to guide Protas in achieving its non-profit mission of tackling the immense global burden of common diseases by rethinking clinical trials. 

Prof Sir Martin Landray said: “I am delighted that Richard is joining Protas as Chief Scientist. He brings a wealth of experience in the design and delivery of efficient clinical trials leading to worldwide changes in healthcare and has a strong background in clinical medicine. 

“Under Richard’s leadership we are expanding our Science team to deliver on our promise to design and deliver smart clinical trials to tackle common causes for ill health.”